Home
Mercati
Grafici & Idee
Algo
Notizie
Store
Broker
Scarica
Calendario Economico
Segnali di Trading
Terminale Web
Digita
/
per cercare: @user, $symbol
Cerca
Accedi
Crea un account
Italiano
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Français
Türkçe
ESLA
#3530
Estrella Immunopharma, Inc. Common Stock
1.2
2
+0.83%
Settore:
Base:
Valuta di Profitto:
Intervallo Giornaliero
Intervallo Annuale
Variazione giornaliera
+0.83%
Variazione Mensile
+10.91%
Variazione di 6 mesi
+29.79%
Variazione Annuale
+25.77%
Chiusura Precedente
1.2
1
Open
1.2
2
Bid
Ask
Low
1.2
2
High
1.2
2
Volume
1
Mercati
Mercato Azionario Statunitense
Salute
ESLA
Open full chart
Financials
Overview
Estratto Conto
Statistics
Dividends
Quarterly
Annual
Value
Q1, 25
Q2, 25
Q3, 25
TTM
Key stats
Total common shares outstanding
36.17 M
37.07 M
37.77 M
—
Valuation ratios
Enterprise value
33.13 M
34.28 M
41.83 M
149.91 M
Price to earnings ratio
0.67
0.77
-2.67
-0.42
Price to sales ratio
—
—
—
—
Price to cash flow ratio
-3.55
-9.96
-10.93
-25.78
Price to book ratio
2.17
-13.13
-2.41
-12.16
Enterprise value to EBITDA ratio
—
—
—
—
Profitability ratios
Return on assets %
-0.86
-1.86
-1.36
-4.99
Return on equity %
1.15
0.91
0.49
-1.98
Return on invested capital %
169.42
-275.15
-152.12
361.44
Gross margin %
—
—
—
—
Operating margin %
—
—
—
—
EBITDA margin %
—
—
—
—
Net margin %
—
—
—
—
Liquidity ratios
Quick ratio
—
—
—
—
Current ratio
0.22
0.16
0.15
1.28
Inventory turnover
—
—
—
—
Asset turnover
—
—
—
—
Solvency ratios
Debt to assets ratio
—
—
—
—
Debt to equity ratio
—
—
—
—
Long term debt to total assets ratio
—
—
—
—
Long term debt to total equity ratio
—
—
—
—
Per share metrics
Operating cash flow per share
-0.01
-0.01
-0.02
-0.11
EBIT per share
—
—
—
—
EBITDA per share
—
—
—
—
Total debt per share
—
—
—
—
Cash per share
0.01
0.04
0.04
0.14
Net current asset value per share
0.03
0.04
0.05
0.18
Tangible book value per share
-0.05
-0.17
-0.27
-0.48
Working capital per share
-0.09
-0.21
-0.31
-0.63
Book value per share
-0.05
-0.17
-0.27
-0.48
Notizie
Estrella riporta tasso di risposta completa del 100% in trial sul linfoma
Estrella reports 100% complete response rate in lymphoma trial
Estrella presenterà i dati della fase 1 sulla terapia cellulare mirata a CD19
Estrella to present phase 1 data on CD19-targeted cell therapy
Estrella Immunopharma riceve avviso dal Nasdaq per ritardo nell’assemblea annuale
Estrella Immunopharma receives Nasdaq notice for delayed annual meeting
Estrella Immunopharma chiude un’offerta diretta registrata di 8 milioni di dollari
Estrella Immunopharma closes $8 million registered direct offering
Il titolo di Estrella Immunopharma crolla dopo l’annuncio di un’offerta di 8 milioni
Estrella Immunopharma stock falls after announcing $8 million offering
Estrella Immunopharma raccoglie 8 milioni di dollari tramite offerta registrata
Estrella Immunopharma raises $8 million through registered offering